Retatrutide Research Guide: Triple GLP-1/GIP/Glucagon Receptor Agonist for Obesity and Metabolic Disease

Research Guide | 2026-04-17 | 8.5 min read

Comprehensive research guide on Retatrutide (LY3437943), a triple GLP-1/GIP/Glucagon receptor agonist. Learn about unprecedented weight loss outcomes, mechanism of action, and quality sourcing for obesity research.

Tirzepatide: Dual Incretin Therapy Revolution

Tirzepatide is a novel 39-amino acid peptide (1447.4 Daltons) combining GIP and GLP-1 receptor agonism. This dual mechanism represents a breakthrough in treating type 2 diabetes and obesity.

Key Characteristics

  • Dual GIP/GLP-1 receptor agonist
  • 39-residue modified peptide structure
  • Weekly subcutaneous administration
  • Extended half-life through albumin binding

Clinical Performance

Clinical trials showed remarkable efficacy with HbA1c reductions of 1.5-2.5% and sustained weight loss up to 20% of initial body weight.

---

Research disclaimer: Compiled from published literature. Laboratory research use only.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.

Research peptide catalogSupplier checklistMore peptide guides